Researchers from Kwame Nkrumah University of Science and Technology Describe Findings in Heart Failure (Review of novel therapeutic targets for…

Researchers from Kwame Nkrumah University of Science and Technology Describe Findings in Heart Failure (Review of novel therapeutic targets for improving heart failure treatment based on experimental and clinical studies)

By a News Reporter-Staff News Editor at Drug Week -- Investigators discuss new findings in Heart Disorders and Diseases. According to news originating from Kumasi, Ghana, by NewsRx correspondents, research stated, "Heart failure (HF) is a major public health priority due to its epidemiological transition and the world's aging population. HF is typified by continuous loss of contractile function with reduced, normal, or preserved ejection fraction, elevated vascular resistance, fluid and autonomic imbalance, and ventricular dilatation."

Our news journalists obtained a quote from the research from the Kwame Nkrumah University of Science and Technology, "Despite considerable advances in the treatment of HF over the past few decades, mortality remains substantial. Pharmacological treatments including beta-blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and aldosterone antagonists have been proven to prolong the survival of patients with HF. However, there are still instances where patients remain symptomatic, despite optimal use of existing therapeutic agents. This understanding that patients with chronic HF progress into advanced stages despite receiving optimal treatment has increased the quest for alternatives, exploring the roles of additional pathways that contribute to the development and progression of HF. Several pharmacological targets associated with pathogenesis of HF have been identified and novel therapies have emerged."

According to the news editors, the research concluded: "In this work, we review recent evidence from proposed mechanisms to the outcomes of experimental and clinical studies of the novel pharmacological agents that have emerged for the treatment of HF."

For more information on this research see: Review of novel therapeutic targets for improving heart failure treatment based on experimental and clinical studies. Therapeutics and Clinical Risk Management, 2016;12():887-906. Therapeutics and Clinical Risk Management can be contacted at: Dove Medical Press Ltd, PO Box 300-008, Albany, Auckland 0752, New Zealand (see also Heart Disorders and Diseases).

The news correspondents report that additional information may be obtained from K.O. Bonsu, Kwame Nkrumah Univ Sci & Technol, Coll Hlth Sci, Dept. of Clin & Social Pharm, Kumasi, Ghana. Additional authors for this research include I.K. Owusu, K.O. Buabeng, D.D. Reidpath and A. Kadirvelu.

Keywords for this news article include: Kumasi, Ghana, Africa, Heart Disorders and Diseases, Cardiovascular Diseases, Peptide Hormones, Heart Failure, Heart Disease, Angiotensins, Pharmacology, Cardiology, Autacoids, Therapy, Kwame Nkrumah University of Science and Technology.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2016, NewsRx LLC